Search results for "temi"

showing 10 items of 3194 documents

SHIP2: A “NEW” Insulin Pathway Target for Aging Research

2014

Strong evidence suggests that systemic inflammation and central adiposity contribute to and perpetuate metabolic syndrome. All of these alterations predispose individuals to type 2 diabetes mellitus (T2DM), cardiovascular disease, as well as Alzheimer's disease (AD), all characterized by chronic inflammatory status. On the other hand, extensive abnormalities in insulin and insulin-like growth factor I (IGF-I) and IGF-II signaling mechanisms in brains with AD have been demonstrated, suggesting that AD could be a third form of diabetes. The Src homology domain-containing inositol 5-phosphatase 2 (SHIP2) has an important role in the insulin pathway because its over-expression causes impairment…

AdultAgingmedicine.medical_specialtymedicine.medical_treatmentDiseaseBiologySystemic inflammationPolymorphism Single Nucleotidepolymorphismchemistry.chemical_compounddomain-containing inositol 5-phosphatase 2 (SHIP2) insulin-like growth factor I (IGF-I) type 2 diabetes mellitus (T2DM)INFLAMMATIONGene FrequencyAlzheimer DiseaseDiabetes mellitusInternal medicinemedicineHumansInsulinSettore MED/05 - Patologia ClinicaSNPInositolAgedSettore MED/04 - Patologia GeneraleALZHEIMER’S DISEASEResearchInsulinInositol Polyphosphate 5-PhosphatasesNEURODEGENERATIONType 2 Diabetes Mellitusmedicine.diseasePhosphoric Monoester HydrolasesEndocrinologyDiabetes Mellitus Type 2chemistryImmunologySettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomMetabolic syndromeSignal TransductionRejuvenation Research
researchProduct

Ranking the impact of human health disorders on gut metabolism: Systemic lupus erythematosus and obesity as study cases

2015

Multiple factors have been shown to alter intestinal microbial diversity. It remains to be seen, however, how multiple collective pressures impact the activity in the gut environment and which, if any, is positioned as a dominant driving factor determining the final metabolic outcomes. Here, we describe the results of a metabolome-wide scan of gut microbiota in 18 subjects with systemic lupus erythematosus (SLE) and 17 healthy control subjects and demonstrate a statistically significant difference (p < 0.05) between the two groups. Healthy controls could be categorized (p < 0.05) based on their body mass index (BMI), whereas individuals with SLE could not. We discuss the prevalence of SLE c…

AdultAutoimmunityGut floramedicine.disease_causeArticleAutoimmunityBody Mass IndexmedicineHomeostasisHumansLupus Erythematosus SystemicMetabolomicsClinical significanceMicrobiomeObesityMultidisciplinaryLupus erythematosusbiologyMicrobiotaCase-control studyMiddle Agedmedicine.diseasebiology.organism_classificationObesityN-Acetylneuraminic AcidGastrointestinal TractCase-Control StudiesImmunologyMetabolomeFemaleMicrobiomeBody mass indexMetabolic Networks and PathwaysScientific Reports
researchProduct

The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commerc…

1999

Lupus anticoagulants (LAs) belong to acquired circulating anticoagulants interfering with phospholipid-dependent coagulation tests. Owing to the remarkable variability among patients, SSC guidelines recommend more than one test to detect and confirm the presence of LAs. However, this is an expensive procedure and greatly raises the work load of the laboratory. A standardised platelet-derived phospholipid preparation was obtained and platelet neutralisation (PNP) procedures with APTT and DRVVT reagents were performed on plasmas from 16 patients with LAs and from 41 control subjects. In comparisons, STAclot-PNP and DVVconfirm clotting assays were conducted. PNP by using APTT or DRVVT reagents…

AdultBlood PlateletsMaleinorganic chemicalsAdolescentmedicine.drug_classCoefficient of variationCoagulation testingHumansMedicineheterocyclic compoundsPlateletPhospholipidsAgedBlood coagulation testCryopreservationLupus anticoagulantChromatographySystemic lupus erythematosusbusiness.industryAnticoagulantHematologyMiddle Agedmedicine.diseaseControl subjectsenzymes and coenzymes (carbohydrates)Freeze DryingLupus Coagulation InhibitorImmunologyFemaleBlood Coagulation TestsbusinessThrombosis Research
researchProduct

Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

2017

Summary T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the pathogenesis of several autoimmune diseases. The exact role of IL-9 and Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β expression were assessed in skin and kidney biopsies of SSc patients and healthy controls (HC) by immunohistochemistry (IHC). The cellular source of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-producing cells were also studied by flow cytometry. The functional relevance of IL-9 increased expression in SSc …

AdultCD4-Positive T-LymphocytesMale0301 basic medicineIL-9 ILC2 systemic sclerosis Th9Thymic stromal lymphopoietinNeutrophilsImmunologyExtracellular TrapsPeripheral blood mononuclear cellFlow cytometryILC2Pathogenesis03 medical and health sciencesThymic Stromal LymphopoietinTransforming Growth Factor betaProto-Oncogene ProteinsmedicineHumansImmunology and AllergyTh9Interleukin 9Mast CellsAutoantibodiesSkinReceptors Interleukin-9B-LymphocytesScleroderma Systemicmedicine.diagnostic_testintegumentary systembusiness.industryInterleukin-9InterleukinCell DifferentiationOriginal ArticlesNeutrophil extracellular trapsMiddle AgedIL-9Settore MED/16 - Reumatologia030104 developmental biologyImmunologyTrans-ActivatorsCytokinesImmunohistochemistryFemaleInterleukin-4businesssystemic sclerosi
researchProduct

Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network

2021

Background: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. Methods: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. Results: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as…

AdultCancer Researchbone sarcomacisplatinsystemic treatmentchemotherapyDisease-Free SurvivalTreatment OutcomeOncologyimatinibImatinib MesylateHumansProspective StudieschordomaRetrospective Studies
researchProduct

RDW in patients with systemic lupus erythematosus. Influence of anaemia and inflammatory markers

2013

Red blood cell distribution width (RDW) is a routine parameter that reflects size variations in erythrocytes. High RDW has been associated with cardiovascular events and inflammatory diseases. However, no studies evaluating the association of RDW with systemic lupus erythematosus (SLE) have been published. We aimed to explore the association of RDW with inflammatory markers in SLE. As SLE is often associated with anaemia, we considered this factor in order to know whether RDW is related with inflammation, anaemia or both in SLE. The study included 105 SLE patients (7 men, 98 women; aged 15-73 years) and 105 controls (9 men, 96 women; aged 18-71 years). Patients were divided according to ana…

AdultErythrocyte IndicesMalemedicine.medical_specialtyAdolescentPhysiologyInflammationFibrinogenErythrocyte aggregationGastroenterologyYoung Adultimmune system diseasesPhysiology (medical)Internal medicinemedicineHumansLupus Erythematosus SystemicIn patientYoung adultskin and connective tissue diseasesAgedRetrospective StudiesInflammationLupus erythematosusbusiness.industryAnemiaRetrospective cohort studyRed blood cell distribution widthHematologyMiddle Agedmedicine.diseaseImmunologyFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

ProC® Global Assay in the Evaluation of Women with History of Severe Preeclampsia or HELLP Syndrome

2003

Preeclampsia/HELLP syndrome has been associated with a high incidence of defects in the protein C pathway and increased anticardiolipin-antibodies/lupus anticoagulants. It is also apparent that thrombophilia is responsible for other pregnancy complications, such as recurrent spontaneous abortion, fetal growth restriction, intrauterine fetal death, and abruptio placentae. ProC® Global is a new global clotting assay designed to evaluate the abnormalities in the protein C anticoagulant pathway. It is based on the ability of endogenous activated protein C, generated by activation of protein C by Protac®, to prolong an activated partial thromboplastin time. A total of 61 patients with a history…

AdultHELLP Syndromemedicine.medical_specialtyHELLP syndrome030204 cardiovascular system & hematologyThrombophiliaSensitivity and SpecificityGastroenterologyProtein SPreeclampsia03 medical and health sciences0302 clinical medicinePre-EclampsiaPregnancyInternal medicinemedicineHumansThrombophilia030212 general & internal medicineBlood coagulation testSystemic lupus erythematosusmedicine.diagnostic_testbiologybusiness.industryHematologyGeneral Medicinemedicine.diseaseCase-Control StudiesImmunologybiology.proteinFemaleBlood Coagulation TestsReagent Kits DiagnosticbusinessBiomarkersProtein CProtein Cmedicine.drugPartial thromboplastin timeClinical and Applied Thrombosis/Hemostasis
researchProduct

Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunc…

2015

Abstract Background Cirrhotic cardiomyopathy may lead to heart failure in stressful circumstances, such as after transjugular intrahepatic portosystemic shunt (TIPS) placement. Aim To examine whether acute volume expansion predicts haemodynamic changes after TIPS and elicits signs of impending heart failure. Methods We prospectively evaluated refractory ascites patients (group A) and compensated cirrhotics (group B), who underwent echocardiography, NT-proBNP measurement, and heart catheterization before and after volume load; group A repeated measurements after TIPS. Results 15 patients in group A (80% male; 54 ± 12.4 years) and 8 in group B (100% male; 56 ± 6.2 years) were enrolled. Echoca…

AdultLiver CirrhosisMaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatmentCardiac indexDiastoleElectrocardiographyInternal medicineNatriuretic Peptide BrainmedicineHumansProspective StudiesPulmonary wedge pressureAgedCardiac catheterizationHeart Failure DiastolicHepatologybusiness.industryHemodynamicsGastroenterologyAscitesMiddle Agedmedicine.diseasePeptide Fragmentsmedicine.anatomical_structureEchocardiographySpainHeart failureHeart catheterizationVascular resistanceCardiologyFemaleVascular ResistancePortasystemic Shunt Transjugular IntrahepaticbusinessTransjugular intrahepatic portosystemic shuntDigestive and Liver Disease
researchProduct

Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis

2011

Background and aims Portal vein thrombosis (PVT) negatively impacts the prognosis in patients with cirrhosis. The aim of our study was to evaluate the effects of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with cirrhosis complicated by PVT. Methods Seventy consecutive cirrhotic patients with non-tumoural PVT treated with TIPS for portal hypertension complications from January 2003 to February 2010 in a tertiary-care centre were followed until last clinical evaluation, liver transplantation, or death. Results TIPS was successfully placed without major procedure-related complications. After TIPS, the portal venous system was completely recanalised in 57% of pati…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisvenous thrombosimedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatePortal venous systemLiver transplantationmeta-analysiSettore MED/01 - Statistica MedicaSpontaneous bacterial peritonitistransjugular intrahepatic portosystemic shuntmedicineHumansAgedVenous ThrombosisPortal Veinbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseLiver TransplantationPortal vein thrombosisSurgeryVenous thrombosisrisk-factorTreatment OutcomeLiver-transplantationPortal hypertensionFemaleRadiologyPortasystemic Shunt Transjugular IntrahepaticEpidemiologic MethodsTomography X-Ray ComputedbusinessTransjugular intrahepatic portosystemic shuntLiver Circulation
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct